May Measurement Month 2018: an analysis of blood pressure screening results from Indonesia

Yuda Turana1†, Bambang Widyantoro2†, Tunggul D. Situmorang3, Juzi Delliana4, Rully M.A. Roesli5, Siska S. Danny2, Suhardjono6, Yulia Sofiatin7, Eka Hermiawaty8, Ario S. Kuncoro2, RossanaBarack9, Thomas Beaney10,11, Anca Chis Ster10, Neil R. Poulter10, and Anwar Santoso2*

1Department of Neurology, School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia;  
2Department of Cardiology — Vascular Medicine, Faculty of Medicine, Universitas Indonesia — National Cardiovascular Center Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta 11420, Indonesia;  
3Division of Nephrology, Department of Internal Medicine, PGI Cikini Hospital, Jakarta 10330, Indonesia;  
4Department of Cardiology, Directorate of Non-Communicable Disease, Ministry of Health - Republic of Indonesia, Jalan Percetakan Negara 29, Jakarta 10560, Indonesia;  
5Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Hasan Sadikin General Hospital, Bandung 40161, Indonesia;  
6Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia—Cipto Mangunkusumo National General Hospital, Jalan Pangeran Diponegoro No: 71, Jakarta 10430, Indonesia;  
7Department of Public Health, Faculty of Medicine, Padjadjaran University, Jalan Prof. Eijkman 38, Bandung 40161, Indonesia;  
8Department of Neurology, National Cardiovascular Center Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta 11420, Indonesia;  
9Department of Cardiology, MMC Hospital, Jakarta, Indonesia;  
10Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, Shepherd’s Bush, London W12 7RH, UK; and  
11Department of Primary Care and Public Health, Imperial College London, St Dunstan’s Road, London W6 8RP, UK

*Corresponding author. Tel: +62 21 5684093, Fax: +62 21 568, Email: anwarsantoso@inaheart.org  
†The first two authors and corresponding author contributed equally to the study.

Published on behalf of the European Society of Cardiology. © The Author(s) 2020.  
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Elevated blood pressure (BP) is a significant burden worldwide, leading to high cardiovascular morbidity and mortality. For the second year of the May Measurement Month (MMM) campaign in Indonesia in 2018, we recruited 174 sites in 31 out of 34 provinces in Indonesia and screened through convenience sampling in public areas and rural primary health centres. Hypertension was defined as systolic BP $\geq 140$ mmHg or diastolic BP $\geq 90$ mmHg, or both, or on the basis of receiving antihypertensive medication. Blood pressure was measured three times followed the standard global MMM protocol, multiple imputation was used to estimate the mean of the 2nd and 3rd BP readings if these were not recorded. A total of 91 222 individuals were screened, and after multiple imputations, 27 331 (30.0%) had hypertension. Of individuals not receiving antihypertensive medication, 14 367 (18.4%) were hypertensive. Among the 47.4% of hypertensive individuals on antihypertensive medication, 10 106 (78.0%) had uncontrolled BP. MMM17 and MMM18 were still the most extensive standardized screening campaigns for BP measurement in Indonesia. Compared to the previous study, the proportion with uncontrolled BP on medication was significantly higher and provided the substantial challenges in managing hypertension in the rural community.

Methods

The Indonesian MMM18 survey is part of the global MMM initiative. It was conducted and funded by the Indonesian Society of Hypertension (InaSH), which includes the Indonesian Heart Association (PERKI), Indonesian Neurological Association (PERDOSSI), and Indonesian Nephrology Association (PERNEFRI); with close collaboration with the Ministry of Health. The ethical clearance was obtained from Universitas Padjajaran, Bandung. We recruited 174 sites in 31 out of 34 provinces of Indonesia, with 318 volunteers registered in our database. For volunteers, information of protocols and directions were given by e-mail communication.

This is a cross-sectional survey with a convenience sampling technique, and this year, we had screened mostly in the primary health centres in communities, and the university. We distributed leaflets on BP awareness during the campaign and emphasized the importance of measuring three BP readings at the sites. Hypertension was defined as systolic BP $\geq 140$ mmHg or diastolic BP $\geq 90$ mmHg, or both, or on the basis of receiving antihypertensive medication. Blood pressure was measured three times followed the standard global MMM protocol and multiple imputation was used to estimate the mean of the 2nd and 3rd BP readings if these were not recorded. Height and weight were estimated. Due to unavailability of automated BP devices in primary health centres at rural communities, only $\sim$35% of measurements were obtained using digital BP devices, while others were measured by manual BP devices. Data collection was done by sending hard copies to the InaSH secretariat or by spreadsheets. Data were cleaned locally by our team and further analysed centrally by MMM analysts.

Results

During May 2018, 91 222 individuals were screened, of whom 68 846 individuals completed three BP readings, with a mean age of $45.0 \pm 16.3$ years and 18.6% of participants were in the age group of 18-29 years old. More women (59%) than men (41%) were screened. About 14.2% of participants were taking antihypertensive medications, 3651 (4.0%) participants reported having diabetes, 1536 (1.7%) reported a history of myocardial infarction (MI), 897 (1.0%) had a history of stroke, and 9365 (10.3%) were active smokers. The mean body mass index was 23.7 $\pm$ kg/m$^2$ (Supplementary material online, Table S1).

Among 68 846 participants with three BP readings, the mean of the 2nd and 3rd readings was lower than the first reading (Supplementary material online, Table S2). After
imputation, 27 331 (30.0%) were hypertensive. Of those who were hypertensive, 13 018 (47.6%) individuals were aware of having hypertension and 12 964 (47.4%) were being treated with antihypertensive medication, of whom 10 106 (78.0%) still had uncontrolled BP.

We observed that individuals receiving antihypertensive medications had significantly higher systolic and diastolic BPs than those who were not. In contrast, after adjusting for age, sex, and antihypertensive treatment, systolic and diastolic BPs were significantly lower in those with diabetes and those with a previous history of MI. Only systolic BP was lower in smokers (Supplementary material online, Figure S1). Overweight and obese participants (vs. healthy weight) were associated with higher systolic and diastolic BPs. Conversely, underweight vs. healthy weight participants were associated with lower systolic and diastolic BPs (Supplementary material online, Figure S2). Our study also found that diastolic BP was lower on Fridays and Saturdays (weekends) compared to measurements taken on Mondays.

Discussion

In this survey, the proportion of participants with hypertension was 30.8%, lower than the worldwide data of 33.4% and from the region of South-East Asia and Australasia with 35.4%. The mean BP from the 2nd and 3rd readings was 123.3/78.3 mmHg, comparable to worldwide data of 122.5/77.7 mmHg. The median age of our participants was 45, with a higher proportion in the group of 18-29 years old than in older age groups, which may in part explain the lower proportion of high BP compared to our MMM17 data with 34.5%.

The major difference in Indonesian MMM18 was the participation of the screening sites. About 70% of screening sites were in primary health care settings, with successful application of three BP readings in most of those sites, in line with our advocacy to the government following last year's recommendation. While we could reach only 31 of 34 provinces in the country this year, the distribution of screening sites was wider and reached more rural areas as compared to 2017. This may reflect in some of the findings this year, as we observed proportion of individuals on antihypertensive medication who have not achieved target BP (78%) is significantly higher as compared to global data of 40.0%, and indeed reflects the significant burden of managing hypertension in our community. However, in concordance with our MMM17 results, we observed that individuals with diabetes or a previous history of MI had significantly lower BPs than those without these conditions.

Again, this finding suggested a possible better awareness of BP control in individuals who had suffered from hypertension-medicated organ damage.

We observed the mean systolic BP in women is higher than in men over 65 years of age (Supplementary material online, Figure S3) but is lower at a young age (excluding subjects on medication), while diastolic BP shows similar pattern both in men and women. This is in contrast to the global studies which show that an increase in systolic BP occurs at the age of over 75 years, where diastolic BP shows an inverted U shape in line with the increased age.

Despite the study limitations that has been described in the global MMM18 publication, the Indonesian MMM18 campaign was useful and provided reliable evidence to support further advocacy for public health policymaking.

Supplementary material

Supplementary material is available at European Heart Journal Supplements online.

Acknowledgements

The authors gratefully thank the Ministry of Health, Republic of Indonesia, leaders and members of InaSH, PERKI, PERNEFRI, and PERDOSI, all volunteers and site leaders, the secretary and data analyst team in InaSH, and all MMM global team for the tremendous efforts. The authors appreciated Omron for donating digital BP devices.

Funding

Indonesian Society of Hypertension (InaSH) including the Indonesian Heart Association (PERKI), Indonesian Neurological Association (PERNEFRI) and Indonesian Nephrology Association (PERDOSSI) funded the study.

Conflict of interest: N.R.P. reported grants from Servier and Pfizer, personal fees from Servier and fees for arranging and speaking at educational meeting from AstraZeneca. A.S. declared that he had educational fees from AstraZeneca, Boehringer-Ingelheim, Pfizer and Servier. He had research grants from PHRI (Population Health Research Institute), Hamilton-Canada. He holds no stocks or shares in any such companies. The remaining authors reported that they had no conflict of interest related to this study.

References

1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Ezzet K, Hassen Abate K, Kanjiyemiyuji TF, Ali R, Adis-Guzman H, Azzopardi P, Banerjee A, Banghaguen A, Basu A, Bekele T, Bennett DA, Bledglagen S, Catalla-Lopez F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hanken GJ, Jonas JB, Judd SE, Kangan YH, Khosravi A, Kim YJ, Kamioko RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Mekenduy AA, Mensah GA, Missanow A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalef F, Rayaf A, Ral RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sejourly SG, Shiga GT, Shliau I, Tedla BA, Thrift AG, Tonelli M, Truefens T, Tsilimparis N, Ukaja KKT, Uthman QO, Vasaiki T, Venkatedasumran N, Vlassov VV, Vos T, Westernman R, Yan LL, Yano Y, Yonemoto N, Zakve M, Murray CJ. Global Burden of Hypertension and Systolic Blood Pressure of at Least105 to 115 mm Hg. 1990-2015. JAMA 2017;317:165-182.

2. Arita H, Barzi F, Chalmers J. Mortality patterns in hypertension. J Hypertens 2011;29(Suppl 1):S5-57.

3. Krishnan A, Garg R, Kahandilyanage A. Hypertension in the South-East Asia Region: an overview. Reg Health Forum 2013;17:7-14.

4. Castillo R. SSA 03-1 prevalence and management of hypertension in Southeast Asia. J Hypertens 2016;34:e4.

5. Gupta R. SSA 02-3 trend in hypertension epidemiology in South Asia. J Hypertens 2016;34:e2.

6. Suh I. PL 01-2 blood pressure and cardiovascular disease mortality in the Asia Pacific Region. J Hypertens 2016;34:e11.

7. Indonesian Primary Health Survey Report, 2018. Ministry of Health Republic of Indonesia, National Health Research and Development, Ministry of Health Republic of Indonesia, Jakarta; 2018.
8. World Health Organization (WHO). *A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis: World Health Day 2013*. Geneva: WHO; 2013.

9. Legorreta AP, Schaff SR, Leibowitz AN, van Meijgaard J. Measuring the effects of screening programs in asymptomatic employees: detection of hypertension through worksite screenings. *J Occup Environ Med* 2015;57:682-686.

10. Widyantoro B, Situmorang TD, Turana Y, Barack R, Delliana J, Roesli RMA, Erwinanto E, Hermiawaty E, Kuncoro AS, Sofiatin Y, Beaney T, Xia X, Poulter NR, Schlaich MP, Santoso A; MMM Indonesia Investigators. May Measurement Month 2017: an analysis of the blood pressure screening campaign results in Indonesia-South-East Asia and Australasia. *Eur Heart J Suppl* 2019;21(Suppl D):D63-D65.

11. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP, Schutte AE, Tomaszewski M, Touyz R, Wang JC, Weber MA, Poulter NR; MMM Investigators. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. *Eur Heart J* 2019;40:2006-2017.